Acanya (Clindamycin)

Generic Name

Clindamycin

Brand Names

Acanya, Altreno, Atralin, Cleocin, ClindaCare, Clindacin, Clindacin ETZ, Clindagel, Clindamycin Phoaphate, Clindesse, Neuac, Onexton, Renova, Retin-A, Tretinoin, Tri-Luma, Twyneo, Xaciato, ZIANA

FDA approval date: May 22, 1970

Classification: Retinoid

Form: Solution, Lotion, Injection, Suppository, Cream, Aerosol, Kit, Granule, Powder, Swab, Capsule, Gel

What is Acanya (Clindamycin)?

ACANYA ® Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. ACANYA Gel is a combination of clindamycin phosphate and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years or older.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation

Enrollment Status: Recruiting

Publish Date: October 28, 2026

Intervention Type: Diagnostic test, Procedure, Device

Study Phase: Not Applicable

Summary: Pneumatization of the maxillary sinus may lead to insufficient bone volume for dental implant placement in the edentulous posterior maxilla. Sinus floor elevation (SFE) surgery with the lateral window technique is a safe and predictable surgical intervention to restore bone height in the maxillary premolar and molar areas. According to the literature, several bone graft materials may be successful...

A Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy

Enrollment Status: Recruiting

Publish Date: October 23, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

Enrollment Status: Recruiting

Publish Date: October 20, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

View All Clinical Trials